(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 21 July 2005 (21.07.2005)

PCT

(10) International Publication Number WO 2005/066182 A1

(51) International Patent Classification⁷: C07D 495/04

(21) International Application Number:

PCT/JP2005/000318

(22) International Filing Date: 6 January 2005 (06.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2004-001310 6 January 2004 (06.01.2004) J.

(71) Applicant (for all designated States except US): TAISHO PHARMACEUTICAL CO., LTD. [JP/JP]; 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NAKAZATO, Atsuro [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). OKUBO, Taketoshi [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). NOZAWA, Dai [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). TAMITA, Tomoko [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). KENNIS, Ludo, E.J. [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, Beerse, B-2340 (BE).

(74) Agents: ASAMURA, Kiyoshi et al.; Room 331, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo, 1000004 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

with international search report

 before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP



(57) Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound,

inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

1

DESCRIPTION

THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP

DETAILED DESCRIPTION OF THE INVENTION

TECHNICAL FIELD

The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc.

10

15

20

25

DESCRIPTION OF THE PRIOR ART

CRF is a hormone comprising 41 amino acids (Science, 213, 1394-1397, 1981; and J. Neurosci., 7, 88-100, 1987), and it is suggested that CRF plays a core role in biological reactions against stresses (Cell. Mol. Neurobiol., 14, 579-588, 1994; Endocrinol., 132, 723-728, 1994; and Neuroendocrinol. 61, 445-452, 1995). For CRF, there are the following two paths: a path by which CRF acts on peripheral immune system or sympathetic nervous system through hypothalamus-pituitary-adrenal system, and a path by which CRF functions as a neurotransmitter in central nervous system (in Corticotropin Releasing Factor: Basic and Clinical Studies of a Neuropeptide, pp. 29-52, 1990). Intraventricular administration of CRF to hypophysectomized rats and normal rats causes an anxiety-like symptom in both types of rats (Pharmacol. Rev., 43, 425-473, 1991; and Brain Res. Rev., 15, 71-100, 1990). That is, there are suggested the participation of CRF in hypothalamus-pituitary-adrenal system and the pathway by which CRF functions as a neurotransmitter in central nervous system.

The review by Owens and Nemeroff in 1991 summarizes diseases in which CRF is involved (Pharmacol. Rev., 43, 425-474, 1991). That is, CRF is

2

involved in depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, inflammation, immunity-related diseases, etc. It has recently been reported that CRF is involved also in epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, and cephalic external wound (Brain Res. 545, 339-342, 1991; Ann. Neurol. 31, 48-498, 1992; Dev. Brain Res. 91, 245-251, 1996; and Brain Res. 744, 166-170, 1997). Accordingly, antagonists against CRF receptors are useful as therapeutic agents for the diseases described above.

WO02/002549, WO97/29110 and WO98/47903 disclose thienopyridine and thienopyrimidine derivatives respectively as CRF receptor antagonists. However, none disclose the compounds provided in the present invention.

PROBLEM(S) TO BE SOLVED BY INVENTION

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.

MEANS FOR SOLVING PROBLEM

25

The present inventors earnestly investigated thienopyrimidine or thienopyridine derivatives substituted with a cyclic amino group that have a high affinity for CRF receptors, whereby the present invention has been accomplished.

The present invention is thienopyrimidine or thienopyridine derivatives substituted with a cyclic amino group explained below.

A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:

$$X-(CHR^3)_{\overline{h}}-(CR^1R^2)_{\overline{m}}$$

$$R^4$$

$$R^5$$

$$R^6$$

$$R^6$$

5

(wherein the cyclic amino group is represented by the following formula [II]:

10

15

in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C_{1-5} alkylene or C_{1-4} alkylene-O- C_{1-4} alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by - $(CR^1R^2)_m$ - $(CHR^3)_n$ -X, R^4 and R^5 independently on the same or different carbon atoms of the cyclic amine;

X is cyano, hydroxy, -CO₂R⁸ or -CONR⁹R¹⁰;

Y is N or CR¹¹;

R¹ is hydrogen, hydroxy, C₁₋₅alkyl, C₁₋₅alkoxy-C₁₋₅alkyl or hydroxy-C₁₋₅

20 salkyl;

R² is hydrogen or C₁₋₅alkyl;

R³ is hydrogen, cyano, C₁₋₅alkyl, C₁₋₅alkoxy-C₁₋₅alkyl or hydroxy-C₁

5alkyl;

m is an integer selected from 0, 1, 2, 3, 4 and 5;

n is 0 or 1;

 R^4 is hydrogen, hydroxy, hydroxy- $C_{1\text{--}5}$ alkyl, cyano, cyano- $C_{1\text{--}5}$ alkyl or $C_{1\text{--}5}$ alkyl;

R⁵ is hydrogen or C₁₋₅alkyl;

R⁶ is hydrogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, 30 hydroxy, C₁₋₅alkoxy, C₃₋₈cycloalkyloxy, halogen, C₁₋₅alkylthio or -N(R¹²)R¹³;

R⁷ is hydrogen, halogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, hydroxy, C₁₋₅alkoxy, C₃₋₈cycloalkyloxy, -N(R¹⁴)R¹⁵, -CO₂R¹⁶, -CON(R¹⁷)R¹⁸, cyano, nitro, C₁₋₅alkylthio, trifluoromethyl or trifluoromethoxy;

4

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, $C_{1\text{-}5}$ alkyl, $C_{3\text{-}8}$ cycloalkyl, $C_{2\text{-}5}$ alkenyl, $C_{2\text{-}5}$ alkynyl, $C_{1\text{-}5}$ alkoxy, $C_{1\text{-}5}$ alkylthio, $C_{1\text{-}5}$ alkylsulfinyl, $C_{1\text{-}5}$ alkylsulfonyl, cyano, nitro, hydroxy, $-CO_2R^{19}$, $-C(=O)R^{20}$, $-CONR^{21}R^{22}$, $-OC(=O)R^{23}$, $-NR^{24}CO_2R^{25}$, $-S(=O)_rNR^{26}R^{27}$, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and $-N(R^{28})R^{29}$;

 R^8 is hydrogen, C_{1-10} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-5} alkyl, aryl or aryl- C_{1-5} alkyl;

 R^9 and R^{10} are the same or different, and independently are hydrogen, C_{1-5} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-5} alkyl, aryl or aryl- C_{1-5} alkyl; or R^9 and R^{10} form a ring selected from saturated 3 to 8 membered ring with the attached nitrogen atom, wherein one of the carbon atoms of such saturated 3 to 8 membered ring is optionally replaced by an oxygen or sulfur atom or by N-Z wherein Z is hydrogen, benzyl or C_{1-5} alkyl;

R¹¹ is hydrogen, halogen or C₁₋₅alkyl;

 R^{12} , R^{13} , R^{14} and R^{15} are the same or different, and independently are hydrogen or C_{1-5} alkyl;

R¹⁶, R¹⁹ and R²⁵ are the same or different, and independently are hydrogen or C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, aryl or aryl-C₁₋₅alkyl;

 $R^{17},R^{18},R^{20},R^{21},R^{22},R^{23},R^{24},R^{26},R^{27},R^{28} \ and \ R^{29} \ are \ the \ same \ or \ different, and independently are hydrogen, <math>C_{1\text{-}5}$ alkyl or $C_{3\text{-}8}$ cycloalkyl;

r is 1 or 2)

WO 2005/066182

10

15

20

30

, individual isomers thereof or racemic or non-racemic mixtures of
25 isomers thereof, pharmaceutically acceptable prodrugs thereof or pharmaceutically
acceptable salts and hydrates thereof.

The terms used in the present specification have the following meanings.

The term "a 3- to 8-membered saturated cyclic amine" means aziridine, azetidine, pyrrolidine, piperidine, azepane or azocane.

The term " C_{1-5} alkylene" means a straight or branched chain alkylene of 1 to 5 carbon atoms, such as methylene, ethylene, propylene, trimethylene, tetramethylene, pentamethylene or the like.

The term "a 3- to 8-membered saturated cyclic amine bridged with C₁₋

5

10

20

25

30

⁵alkylene or C₁₋₄alkylene-O-C₁₋₄alkylene between any different two carbon atoms of the cyclic amine" includes, for example, 8-azabicyclo[3.2.1]oct-8-yl, 9-azabicyclo[3.3.1]non-9-yl, 7-azabicyclo[2.2.1]hept-7-yl, 3-oxa-7-azabicyclo[3.3.1]non-7-yl and 3-oxa-9-azabicyclo[3.3.1]non-9-yl.

The term " C_{1-5} alkyl" means a straight chain or branched chain alkyl group of 1 to 5 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, *sec*-butyl, pentyl, isopentyl or the like.

The term " C_{1-5} alkoxy" means a straight chain or branched chain alkoxy group of 1 to 5 carbon atoms, such as methoxy, ethoxy, propoxy, isopropyloxy, butoxy, isobutyloxy, pentyloxy, isopentyloxy or the like.

The term " C_{1-5} alkoxy- C_{1-5} alkyl" means a substituted C_{1-5} alkyl group having the above-mentioned C_{1-5} alkoxy group as the substituent, such as methoxymethyl, 2-methoxyethyl, 2-ethoxyethyl or the like.

The term "hydroxy-C₁₋₅alkyl" means a substituted C₁₋₅alkyl group having hydroxy group, such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl or the like.

The term "cyano- C_{1-5} alkyl" means a substituted C_{1-5} alkyl group having cyano group, such as cyanomethyl, 1-cyanoethyl, 2-cyanoethyl, 3-cyanopropyl, 4-cyanobutyl, 5-cyanopentyl or the like.

The term $^{\circ}C_{3-8}$ cycloalkyl $^{\circ}$ means a cyclic alkyl group of 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl or the like.

The term "C₃₋₈cycloalkyl-C₁₋₅alkyl" means a substituted C₁₋₅alkyl group having the above-mentioned C₃₋₈cycloalkyl as the substituent, such as cyclopropylmethyl, 2-cyclopropylethyl, 2-cyclopentylethyl or the like.

The term " C_{3-8} cycloalkyloxy" means a cyclic alkoxy group of 3 to 8 carbon atoms, such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or the like.

The term "halogen" means fluorine, chlorine, bromine or iodine atom.

The term " C_{1-5} alkylthio" means a straight chain or branched chain alkylthio group of 1 to 5 carbon atoms, such as methylthio, ethylthio, propylthio or the like.

The term "C₁₋₅alkylsulfinyl" means a straight chain or branched chain

6

alkylsulfinyl group of 1 to 5 carbon atoms, such as methylsulfinyl, ethylsulfinyl, propylsulfinyl or the like.

The term " C_{1-5} alkylsulfonyl" means a straight chain or branched chain alkylsulfonyl group of 1 to 5 carbon atoms, such as methylsulfonyl, ethylsulfonyl, propylsulfonyl or the like.

The term "aryl" means a monocyclic or bicyclic group of 6 to 12 ring carbon atoms having at least one aromatic ring, such as phenyl, naphthyl, or the like.

5

10

15

20

The term "heteroaryl" means a monocyclic or bicyclic group of 5 to 12 ring atoms having at least one aromatic ring having in its ring 1 to 4 atoms which may be the same or different and are selected from nitrogen, oxygen and sulfur, such as pyridyl, pyrimidinyl, imidazolyl, quinolyl, indolyl, benzofuranyl, quinoxalinyl, benzo[1,2,5]thiadiazolyl, benzo[1,2,5]oxadiazolyl or the like.

The term "ary- C_{1-5} alkyl" means a substituted C_{1-5} alkyl group having the above-mentioned aryl as the substituent, such as benzyl, phenethyl or the like.

The term " C_{2-5} alkenyl" means a straight chain or branched chain alkenyl group of 2 to 5 carbon atoms, such as vinyl, isopropenyl, allyl or the like.

The term "C₂₋₅alkynyl" means a straight chain or branched chain alkynyl group of 2 to 5 carbon atoms, such as ethynyl, prop-1-ynyl, prop-2-ynyl or the like.

The phrase "aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C_{1-5} alkyl, C_{3-8} cycloalkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{1-5} alkoxy, C_{1-5} alkylthio, C_{1-5} alkylsulfinyl, C_{1-5} alkylsulfonyl, cyano, nitro, hydroxy, $-CO_2R^{19}$, $-C(=O)R^{20}$, $-CONR^{21}R^{22}$, $-OC(=O)R^{23}$, $-NR^{24}CO_2R^{25}$, -

- S(=O)_rNR²⁶R²⁷, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and -N(R²⁸)R²⁹, includes, for example, 2,4-dimethylphenyl, 2,6-dimethylphenyl, 2,4-dibromophenyl, 2-bromo-4-isoproylphenyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 2-chloro-4-trifluoromethylphenyl, 4-methoxy-2-methylphenyl, 2-chloro-4-
- trifluoromethoxyphenyl, 4-isopropyl-2-methylthiophenyl, 2,4,6-trimethylphenyl, 4-bromo-2,6-diethylphenyl, 4-chloro-2,6-diethylphenyl, 4-chloro-2,6-dimethylphenyl, 2,4,6-tribromophenyl, 2,4,5-tribromophenyl, 2,4,6-trichlorophenyl, 2,4,5-trichlorophenyl, 4-bromo-2,6-dichlorophenyl, 6-chloro-2,4-dibromophenyl,

7

2,4-dibromo-6-fluorophenyl, 2,4-dibromo-6-methylphenyl, 2,4-dibromo-6-methoxyphenyl, 2,4-dibromo-6-methylphenyl, 2,6-dibromo-4-isopropylphenyl, 2,6-dibromo-4-trifluoromethylphenyl, 2-bromo-4-trifluoromethylphenyl, 4-bromo-2-methylphenyl, 4-chloro-2-methylphenyl, 2,4-dimethoxyphenyl, 2,6-dimethyl-4-methoxyphenyl, 4-chloro-2,6-dibromophenyl, 4-bromo-2,6-difluorophenyl, 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dichloro-4-trifluoromethoxyphenyl, 2,6-dibromo-4-trifluoromethoxyphenyl, 2-chloro-4,6-dimethylphenyl, 2-bromo-4,6-dimethoxyphenyl, 2-bromo-4-isopropyl-6-methoxyphenyl, 2,4-dimethoxy-6-methylphenyl, 6-dimethylamino-4-methylpyridin-3-yl, 2-chloro-6-trifluoromethylpyridin-3-yl, 2-chloro-6-methoxypyridin-3-yl, 6-methoxy-2-trifluoromethylpyridin-3-yl, 2-chloro-6-difluoromethylpyridin-3-yl, 6-methoxy-2-methylpyridin-3-yl, 2,6-dimethoxypyridin-3-yl, 4,6-dimethyl-2-trifluoromethylpyrimidin-5-yl or 2-dimethylamino-6-methylpyridin-3-yl.

The "pharmaceutically acceptable salts" in the present invention include, for example, salts with an inorganic acid such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid or the like; salts with an organic acid such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, gluconic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid or the like; salts with one or more metal ions such as lithium ion, sodium ion, potassium ion, calcium ion, magnesium ion, zinc ion, aluminium ion or the like; salts with amines such as ammonia, arginine, lysine, piperazine, choline, diethylamine, 4-phenylcyclohexylamine, 2-aminoethanol, benzathine or the like.

15

20

25

30

Prodrugs are also included in this invention. The term "prodrug" means a compound which is converted within the body, e.g. by hydrolysis in the blood, into its active form that has medical effects. The "pharmaceutically acceptable prodrugs" are described in, for example, Advanced Drug Delivery Reviews (1996) 19 (2) 115-130 and Tetrahedron Letter (2002) 43 1161-1164. The "pharmaceutically acceptable prodrugs thereof" in the present invention include, for example, esters such as methyl esters, ethyl esters, and the like when X is

PCT/JP2005/000318

carboxylic acid.

10

20

30

A compound of the present invention includes any isomers such as diastereomers, enantiomers, geometricisomers and tautomeric forms. In a compound represented by formula [I], if the cyclic amino group has one or more chiral carbons and/or if there is an axial chirality between Ar and thienopyrimidine (or thienopyridine) ring, several stereoisomers (diastereomers or enantiomers) can exist. The compound of the present invention includes the individual isomers and the racemic and non-racemic mixtures of the isomers.

Preferable examples of the compound of the present invention are as follows.

$$X-(CHR^3)_{\overline{n}}(CR^1R^2)_m$$

$$R^4 \qquad N \qquad N$$

$$R^6 \qquad [IIII]$$

That is preferable are compounds of the formula [III] in which X, m, n, the cyclic amino group, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and Ar are as defined in above formula [I]. More preferable are compounds of the formula [III] in which X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is 0, 1, 2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and –N(R²⁸)R²⁹ (wherein R²⁸ and R²⁹ are the same or different, and independently are hydrogen or C₁₋₃alkyl). More preferable are compounds of the formula [III] in which X is cyano; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is 0 or 1; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C₁₋₃alkyl.

Other preferable are compounds of the formula [III] in which X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is

0; m is an integer selected from 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{28})R^{29}$ (wherein R^{28} and R^{29} are the same or different, and independently are hydrogen or C_{1-3} alkyl). More preferable are compounds of the formula [III] in which X is hydroxy; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C_{1-3} alkyl.

$$X-(CHR^3)_{\overline{n}}(CR^1R^2)_{\overline{m}}$$

$$R^4 \qquad N \qquad N$$

$$R^5 \qquad R^{11} \qquad R^6$$

10

20

25

30

Other preferable are compounds of the formula [IV] in which X, m, n, the cyclic amino group, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R¹¹ and Ar are as defined in above formula [I]. More preferable are compounds of the formula [IV] in which X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is 0 or 1; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and –N(R²⁸)R²⁹ (wherein R²⁸ and R²⁹ are the same or different, and independently are hydrogen or C₁₋₃alkyl). More preferable are compounds of the formula [IV] in which X is cyano; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is 0 or 1; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; R¹¹ is hydrogen; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C₁₋₃alkyl.

Other preferable are compounds of the formula [IV] in which X is

hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1,2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; R¹¹ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and –N(R²⁸)R²⁹ (wherein R²⁸ and R²⁹ are the same or different, and independently are hydrogen or C₁₋₃alkyl). More preferable are compounds of the formula [IV] in which X is hydroxy; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; R¹¹ is hydrogen; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C₁₋₃alkyl.

The preferable cyclic amino group is a 6-membered saturated cyclic amine.

The preferable R¹ is hydrogen.

10

30

The preferable R² is hydrogen.

The preferable R^3 is hydrogen.

The preferable R⁴ is hydrogen.

The preferable R^5 is hydrogen.

The preferable R^6 is C_{1-3} alkyl. The more preferable R^6 is methyl.

The preferable R^7 is hydrogen or C_{1-3} alkyl.

The preferable R¹¹ is hydrogen.

The preferable Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{28})R^{29}$ (wherein R^{28} and R^{29} are the same or different, and independently are hydrogen or C_{1-3} alkyl). The more preferable Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C_{1-3} alkyl.

Especially preferable compounds of the present invention are:

{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2-methyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-methanol

5

, $\{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]$ piperidin-4-yl}-methanol

10

, 2-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4yl]-piperidin-4-yl}-ethanol

20

, {1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]piperidin-4-yl}-acetonitrile

25

30

, {1-[3-(2,4-dichloro-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}methanol

12

5

 $,\ \{1\hbox{-}[5\hbox{-methyl-}3\hbox{-}(2,4,6\hbox{-trimethyl-phenyl})\hbox{-thieno}[3,2\hbox{-}b]pyridin-7\hbox{-}yl]\hbox{-piperidin-}4$ yl}-methanol

10

, {1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]piperidin-4-yl}-methanol

15

20

, {1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]piperidin-4-yl}-methanol

25

30

, $\{1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl\}$ methanol

5

, $\{1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl\}-methanol$

10

, 2-{1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-

15 piperidin-4-yl}-ethanol

20

, $2-\{1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl\}-ethanol$

25

, 2- $\{1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl\}-ethanol$

30

14

, 2- $\{1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl\}-ethanol$

, 1-[5-methyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b] pyridin-7-yl]-piperidine-3-carbonitrile

10 NC

5

20

15 , {1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile

, {1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile

, $\{1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl\}-30$ acetonitrile

15

5

and $\{1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl\}-acetonitrile.$

10

The compound of the formula [I] can be produced, for example, by the process shown in the following reaction scheme 1 (in the following reaction scheme, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁹, R¹⁰, m, n, X, Y and Ar are as defined above, LG is chloro, bromo, iodo, methanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy or trifluoromethanesulfonyloxy, X^a is carboxy, carbamoyl or – CO₂(C₁₋₅alkyl), X^b is CO₂(C₁₋₅alkyl) or CONR⁹R¹⁰).

20 Reaction Scheme 1

30 Step 1:

Compound (3), a compound of the present invention, can be obtained by reacting Compound (1) with Compound (2) in an inert solvent in the presence or absence of a base. Herein, the base includes, for example, amines such as

16

triethylamine, *N*,*N*-diisopropylethylamine, pyridine and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium *tert*-butoxide and the like; metal amides such as sodium amide, lithium diisopropylamide and the like; and Grignard reagents such as methylmagnesium bromide and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; amides such as *N*,*N*-dimethylformamide, *N*-methylpyrrolidone, *N*,*N*-dimethylacetamide and the like; acetonitrile; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.

10

The compound of the present invention can be converted to a salt in an inert solvent with an inorganic acid such as sulfuric acid, hydrochloric acid, 15 hydrobromic acid, phosphoric acid, nitric acid or the like, with an organic acid such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, 20 glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid or the like, with an inorganic base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide, aluminium hydroxide or the like or with an organic base such as ammonia, arginine, lysine, piperazine, choline, diethylamine, 25 4-phenylcyclohexylamine, 2-aminoethanol, benzathine or the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; esters such as ethyl acetate, ethyl formate and the like; ketones such as acetone, methylethylketone and the like; hydrocarbons such as benzene, toluene and the like; amides such as N,Ndimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.

17

Reaction Scheme 2

$$NC-(CHR^3)_{\overline{n}}-(CR^1R^2)_{\overline{m}}$$

$$R^4 \longrightarrow N$$

$$R^6$$

$$(4)$$

$$X^a-(CHR^3)_{\overline{n}}-(CR^1R^2)_{\overline{m}}$$

$$R^4 \longrightarrow N$$

$$R^5 \longrightarrow N$$

$$R^6$$

$$(5)$$

Step 2:

The cyano group in compound (4), which was synthesized by the similar method described in step 1, can be converted to the carboxyl group, a C₁-10 5alkoxycarbonyl group or the carbamoyl group by using an acid or a base in an inert solvent or without any solvent. An oxidizing agent and/or a crown ether may be used as an additive in this reaction. Herein, the acid includes, for example, organic acids such as formic acid, acetic acid, trifluoroacetic acid, benzenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzoic acid, 15 trifluoromethanesulfonic acid and the like; inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, polyphosphoric acid, nitric acid, boron trifluoride or the like. The base includes, for example, inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydroxide, potassium hydroxide, lithium 20 hydroxide, barium hydroxide and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like. The oxidizing agent includes, for example, hydrogen peroxide, oxygen gas, manganese oxide and the like. The crown ether includes, for example, 18-crown-6, 15-crown-5 and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, 25 isopropyl alcohol, ethylene glycol, tert-butanol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; esters such as ethyl acetate, ethyl formate and the like; amides such as N,N-dimethylformamide, Nmethylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dimethyl 30 sulfoxide; pyridine; chloroform; dichloromethane; water; and mixtures of solvents selected from these inert solvents.

18

Reaction Scheme 3

$$HO_{2}C-(CHR^{3})_{\overline{h}}(CR^{1}R^{2})_{m}$$

$$R^{4}$$

$$R^{5}$$

$$R^{6}$$

$$(6)$$

$$X^{b}-(CHR^{3})_{\overline{h}}(CR^{1}R^{2})_{m}$$

$$R^{4}$$

$$R^{5}$$

$$R^{6}$$

$$(7)$$

Step 3:

5

Compound (7), a compound of the present invention, can be synthesized 10 from Compound (6) by conventional methods for amidating a carboxyl group, esterification of a carboxyl group in the presence or absence of an acid or a base or alkylation of a carboxyl group with an alkylating reagent in an inert solvent. Herein, conventional methods for amidating a carboxyl group or esterification of a carboxyl group are: for example, the reaction via a mixed acid anhydride obtained by the reaction of Compound (6) with haloformic acid ester (e.g., ethyl 15 chloroformate or isobutyl chloroformate) or an acid chloride (e.g., benzoyl chloride or pivaloyl chloride); the reaction in the presence of a condensing agent such as N,N'-dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3ethylcarbodiimide hydrochloride (EDCl), carbonyldiimidazole (CDI), diphenylphosphorylazide (DPPA), diethyl cyanophosphate or the like, optionally an 20 additive such as 1-hydroxybenzotriazole (HOBt), N-hydroxysuccinimide, 4dimethylaminopyridine or the like; or the reaction via an acid halide obtained by the reaction of Compound (6) with a halogenating reagent such as thionyl chloride. oxalyl chloride, or the like. The alkylating reagent is, for example, alkyl halide 25 such as iodomethane, iodoethane, bromomethane, bromoethane and the like. The base includes amines such as triethylamine, N,N-diisopropylethylamine, pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 4-(dimethylamino)pyridine and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate and the like. The acid includes. for example, organic acids such as formic acid, acetic acid, trifluoroacetic acid, 30 benzenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzoic acid, trifluoromethanesulfonic acid and the like; inorganic acids such as sulfuric acid. hydrochloric acid, hydrobromic acid, phosphoric acid, polyphosphoric acid, nitric

acid or the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; esters such as ethyl acetate, ethyl formate and the like; hydrocarbons such as benzene, toluene and the like; amides such as N,N-dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dimethyl sulfoxide; pyridine; chloroform; dichloromethane; water; and mixtures of solvents selected from these inert solvents.

The compound of the present invention is useful as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved. For this purpose, the compound of the present invention can be formulated into tablets, pills, capsules, granules, powders, solutions, emulsions, suspensions, injections and the like by a conventional preparation technique by adding conventional fillers, binders, disintegrators, pH-adjusting agents, solvents, etc.

The compound of the present invention can be administered to an adult patient in a dose of 0.1 to 500 mg per day in one portion or several portions orally or parenterally. The dose can be properly increased or decreased depending on the kind of a disease and the age, body weight and symptom of a patient.

20 ENBODIMENTS OF THE INVENTION

The present invention is concretely explained with reference to the following examples and test example, but is not limited thereto.

Example 1

5

10

15

25

30

Synthesis of {1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-methanol hydrochloride (compound 1-004)

(1) A mixture of 7-(4-bromo-2,6-dimethyl-phenyl)-4-chloro-2,6-dimethyl-thieno[3,2-d]pyrimidine (500 mg), piperidin-4-ylmethanol (226 mg), N,N-

20

diisopropylethylamine (253 mg) in ethanol (1.5 mL) was heated at reflux for 1 day. The reaction mixture was cooled to room temperature, poured into a saturated aqueous sodium hydrogenearbonate, and then extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: hexane/EtOAc = 3 : 1) to obtain {1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl}-methanol as a white solid (568 mg).

- (2) To a suspension of {1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-methanol (568 mg) in a mixture (1:1) of EtOH and EtOAc (2 mL) was added 4 M HCl in EtOAc (0.37 mL) under ice-cooling. The mixture was stirred overnight to afford a white crystal. The crystal was collected by filtration to give the title compound (532 mg).
- Table 1 lists the compound obtained in Example 1 and compounds obtained by the similar procedure as described in Example 1.

Example 2

10

20

30

{1-[7-(4-Bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-acetic acid

(1) A mixture of {1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-acetonitrile (350 mg) and KOH (492 mg) in a mixture of EtOH (1.5 mL) and H₂O (1.0 mL) in a sealed tube was heated at 105 °C for 3 hours. After concentration of the reaction mixture under reduced pressure, 5 % KHSO₄ aqueous solution was added and extracted with CHCl₃. The organic layer was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by a silica gel

column chromatography (silica gel: Wako Gel (C200), eluent: CHCl₃/methanol = 20:1) to obtain the title compound (164 mg).

Table 1 lists the compound obtained in Example 2 and compounds

obtained by the similar procedure as described in Example 2.

Example 3

2-{1-[7-(4-Bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-acetamide

10

15

20

{1-[7-(4-Bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-acetonitrile hydrochloride (30 mg) was dissolved in c H₂SO₄ (0.5 mL) and the solution was stirred at room temperature for 20 hours. After addition of ice, the reaction mixture was made to alkaline (pH 7) with an aqueous NaOH solution and an aqueous NaHCO₃ solution. The mixture was extracted with EtOAc and the organic layer was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: EtOAc) to obtain the title compound (20 mg) as a white crystal.

25 Example 4

{1-[7-(4-Bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-acetic acid ethyl ester

30

$$Br$$
 Br
 Br
 Br
 Br
 Br
 Br

A mixture of {1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-

22

thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-acetic acid (30 mg), iodoethane (97 mg) and K₂CO₃ (17 mg) in DMF (1 mL) was stirred at room temperature for 16 hours. To the reaction mixture were added H₂O and EtOAc and separated. The organic layer was washed brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: Hexane/EtOAc = 4 : 1) to obtain the title compound (22 mg) as a white crystal.

Table 1*I $X-(CHR^3)_{\overline{n}}(CR^1R^2)_{\overline{m}}$ R^7 R^4 R^5 N

5

Com. No.	Ex. No.	X-(CR ² R ³) _n -(CHR ¹) _m R ⁴	Y N-	R ⁶	R ⁷	-Ar	melting point (°C) (solvent for crystallization)
1-001	1	HO-N-	N	CH ₃	Н	CICI	amorphous
1-002	1	HON-	N	CH ₃	Н	CI	amorphous
1-003	1	HON_	N	СН3	Н	H ₃ C H ₃ C	177-180 ^{*2} (EtOAc/EtOH)
1-004	1	HON	N	CH ₃	CH ₃	H ₃ C H ₃ C	242-244 ^{*2} (EtOAc/EtOH)
1-005	1	HO/-N-	N	CH ₃	Н	H ₃ C Br	192-194 ^{*2} (EtOH)
1-006	1	HO—/—N—	N	CH ₃	CH ₃	H ₃ C H ₃ C	192-193 ^{*2} (EtOAc/EtOH)
1-007	1	НО N-	N	CH ₃	Н	CI	amorphous
1-008	1	NC N-	N	CH ₃	Н	CI	amorphous
1-009	1	NC N-	N	CH ₃	Н	H ₃ C ——Br	163-165*2 (EtOAc/EtOH)

1-010	1	NC N-	N	CH ₃	CH ₃	H ₃ C Br	202-204*2 (EtOAc/EtOH)
1-011	1	HO-N-	СН	CH ₃	Н	CICI	amorphous
1-012	1	HON_	СН	СН₃	Н	CI	amorphous
1-013	1	HON-	СН	СН3	Н	H ₃ C CH	amorphous 3
1-014	1	HO N-	СН	CH ₃	Н	H ₃ C Br	228-230*2 (EtOAc/EtOH)
1-015	1	но	СН	СН3	СН3	H ₃ C Br	234-236*2 (EtOAc/EtOH)
1-016	1	HON-	СН	CH ₃	Н	Br Br	196-199*2 (EtOAc/EtOH)
1-017	1	HON-	СН	CH ₃	Н	CI	231-233*2 (EtOAc/EtOH)
1-018	1	HO	СН	CH ₃	Н	H ₃ C Br	172-174*2 (EtOAc)
1-019	1	HON-	СН	СН3	CH ₃	H ₃ C	182-184*2 (EtOAc/EtOH)
1-020	1	HON-	СН	CH ₃	Н	Br Br	166-168*2 (EtOAc/EtOH)
1-021	1	HON-	СН	CH ₃	Н	CI	158-160*2 (EtOAc/EtOH)

			25	<u></u>		
1-022	1	HON_	СН	СН₃	Н	H ₃ C amorphous H ₃ C
1-023	1	NC N-	СН	CH ₃	Н	Cl amorphous ————————————————————————————————————
1-024	1	NC N-	СН	СН3	Н	H ₃ C amorphous H ₃ C
1-025	1	NC_N-	СН	СН3	Н	H ₃ C 186-188*2 —Br (EtOAc/IPE)
1-026	1	NC_N-	СН	CH ₃	СН3	H ₃ C 135-137*2 —Br (EtOAc/EtOH)
1-027	1	NC N-	СН	CH ₃	Н	Br 179-182*2 (EtOAc/EtOH)
1-028	1	NCN-	СН	CH ₃	Н	CI 203-205*2 CI (EtOAc)
1-029	2	HO ₂ C	N	CH ₃	CH ₃	H ₃ C 268-270 Br (EtOAc)
1-030	2	HO ₂ C-\N-	N	CH ₃	CH ₃	H ₃ C 222-224 —Br (EtOAc)
1-031	3	H ₂ NOC N-	N	CH ₃	CH ₃	H ₃ C 212-124*3 H ₃ C
1-032	4	EtO ₂ C	N	CH ₃	CH ₃	H ₃ C 110-112*3

*1: Com. No. = compound number, Ex. No. = example number, solvent for crystallization; EtOAc = ethyl acetate, EtOH = ethanol, IPE = diisopropylether, Et = ethyl

26

Analytical data of non-crystal compounds are described below.

1-001:

MS (Pos, ES): 408 (M + 1)⁺, 410 (M + 3)⁺, 430 (M + Na)⁺, 432 (M + Na + 2)⁺; NMR (300 MHz, CDCl₃) δ 1.50-2.13 (5 H, m), 2.56 (3H, s), 3.48-3.62 (2H, m), 3.71-4.00 (3 H, m), 4.06-4.29 (2 H, m), 7.35 (1 H, dd, J = 2.0, 8.4 Hz), 7.52 (1 H, d, J = 2.0 Hz), 7.57 (1H, d, J = 8.4 Hz), 7.84 (1 H, s)

1-002:

MS (Pos, ES): 408 (M + 1)⁺, 410 (M + 3)⁺; HPLC Retention time: 9.69 (Xterra 10 MS C18 (Waters, Milford, MA) 3.5 μm, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

1-007:

MS (Pos, ES): 436 (M + 1)⁺, 438 (M + 3)⁺; HPLC Retention time: 9.97 (Xterra MS C18 (Waters, Milford, MA) 3.5 μm, 4.6 x 100 mm); Flow rate 1.6 ml/min.

Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

25

30

1-008:

MS (Pos, ES): 403 (M + 1)⁺, 405 (M + 3)⁺; HPLC Retention time: 9.94 (Xterra MS C18 (Waters, Milford, MA) 3.5 μm, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

27

1-011:

MS (Pos, ES): 407 (M + 1)⁺, 409 (M + 3)⁺, 429 (M + Na)⁺, 431 (M + Na + 2)⁺; NMR (300 MHz, CDCl₃) δ 1.20-2.12 (5 H, m), 2.57 (3H, s), 2.80-3.06 (2H, m), 3.52-4.00 (5 H, m), 6.61 (1 H, s), 7.33 (1 H, dd, J = 2.0, 8.4 Hz), 7.51 (1 H, d, J = 2.0 Hz), 7.63 (1H, d, J = 8.4 Hz), 7.73 (1 H, s)

1-012:

MS (Pos, ES): 407 (M + 1)⁺, 409 (M + 3)⁺; HPLC Retention time: 10.02 (Xterra 10 MS C18 (Waters, Milford, MA) 3.5 μm, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

1-013:

MS (Pos, ES): 381 (M + 1)⁺; HPLC Retention time: 9.22 (Xterra MS C18 (Waters, Milford, MA) 3.5 μm, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

25 1-022:

MS (Pos, ES): 409 (M + 1)⁺; HPLC Retention time: 9.89 (Xterra MS C18 (Waters, Milford, MA) 3.5 μm, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

28

MS (Pos, ES): $402 \text{ (M} + 1)^+$, $404 \text{ (M} + 3)^+$; HPLC Retention time: 6.40 (Xterra MS C18 (Waters, Milford, MA) 3.5 μ m, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

1-024:

MS (Pos, ES): 376 (M + 1)⁺; HPLC Retention time: 6.21 (Xterra MS C18 (Waters, Milford, MA) 3.5 μm, 4.6 x 100 mm); Flow rate 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammonium acetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 10 min., to 100 % B in 1 min, 100% B for 3 min. and reequilibrate with 100 % A for 2.5 min)

*2: HCl salt

25

30

*3: Crystallized on standing from the compound purified (silica gel column chromatography) and dried.

Test Example [CRF receptor binding test]

Monkey amygdala membranes were used as a receptor preparation. ¹²⁵I-CRF was used as ¹²⁵I-labeled ligand.

Binding reaction using the ¹²⁵I-labeled ligand was carried out by the following method described in The Journal of Neuroscience, 7, 88 (1987). Preparation of receptor membranes:

Monkey amygdala was homogenized in 50 mM Tris-HCl buffer (pH 7.0) containing 10 mM MgCl₂, 2 mM EDTA and centrifuged at 48,000 x g for 20 min, and the precipitate was washed once with Tris-HCl buffer. The washed precipitate was suspended in 50 mM Tris-HCl buffer (pH 7.0) containing 10 mM MgCl₂, 2 mM EDTA, 0.1% bovine serum albumin and 100 kallikrein units/ml aprotinin, to obtain a membrane preparation.

29

CRF receptor binding test:

The membrane preparation (0.3 mg protein/ml), ¹²⁵I-CRF (0.2 nM) and a test drug were reacted at 25°C for 2 hours. After completion of the reaction, the reaction mixture was filtered by suction through a glass filter (GF/C) treated with 0.3% polyethylene imine, and the glass filter was washed three times with phosphate-buffered saline containing 0.01% Triton X-100. After the washing, the radioactivity of the filter paper was measured in a gamma counter.

The amount of ¹²⁵I-CRF bound when the reaction was carried out in the presence of 1 µM CRF was taken as the degree of nonspecific binding of ¹²⁵I-CRF, and the difference between the total degree of ¹²⁵I-CRF binding and the degree of nonspecific ¹²⁵I-CRF binding was taken as the degree of specific ¹²⁵I-CRF binding. An inhibition curve was obtained by reacting a definite concentration (0.2 nM) of ¹²⁵I-CRF with various concentrations of each test drug under the conditions described above. A concentration of the test drug at which binding of ¹²⁵I-CRF is inhibited by 50% (IC₅₀) was determined from the inhibition curve.

As a result, it was found that compounds 1-003, 1-004, 1-006, 1-010, 1-012, 1-013, 1-014, 1-015, 1-016, 1-017, 1-018, 1-019, 1-020, 1-021, 1-024, 1-025, 1-026, 1-027 and 1-028 can be exemplified as typical compounds having an IC_{50} value of 100 nM or less.

20

25

15

10

EFFECT OF THE INVENTION

According to the present invention, compounds having a high affinity for CRF receptors have been provided. These compounds are effective against diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.

30

CLAIMS

1. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:

$$X-(CHR^3)_{\overline{n}}-(CR^1R^2)_{\overline{m}}$$
 R^4
 R^5
 N
 N
 R^6

(wherein the cyclic amino group is represented by the following formula [II]:

$$X-(CHR^3)_n-(CR^1R^2)_m$$
 R^4
 R^5

in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C_{1-5} alkylene or C_{1-4} alkylene-O- C_{1-4} alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted with a group represented by $-(CR^1R^2)_m$ - $(CHR^3)_n$ -X, R^4 and R^5 independently on the same or different carbon atoms of the cyclic amine;

X is cyano, hydroxy, -CO₂R⁸ or -CONR⁹R¹⁰;

Y is N or CR¹¹;

R¹ is hydrogen, hydroxy, C₁₋₅alkyl, C₁₋₅alkoxy-C₁₋₅alkyl or hydroxy-C₁

5alkyl;

 R^2 is hydrogen or C_{1-5} alkyl;

R³ is hydrogen, cyano, C₁₋₅alkyl, C₁₋₅alkoxy-C₁₋₅alkyl or hydroxy-C₁₋₅

5alkyl;

m is an integer selected from 0, 1, 2, 3, 4 and 5;

n is 0 or 1;

 R^4 is hydrogen, hydroxy, hydroxy- C_{1-5} alkyl, cyano, cyano- C_{1-5} alkyl or C_{1-5} alkyl;

R⁵ is hydrogen or C₁₋₅alkyl;

R⁶ is hydrogen, C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, hydroxy, C₁₋₅alkoxy, C₃₋₈cycloalkyloxy, halogen, C₁₋₅alkylthio or -N(R¹²)R¹³;

31

 R^7 is hydrogen, halogen, $C_{1\text{-}5}$ alkyl, $C_{3\text{-}8}$ cycloalkyl, $C_{3\text{-}8}$ cycloalkyl- $C_{1\text{-}5}$ alkyl, hydroxy, $C_{1\text{-}5}$ alkoxy, $C_{3\text{-}8}$ cycloalkyloxy, -N(R^{14}) R^{15} , -CO₂ R^{16} , -CON(R^{17}) R^{18} , cyano, nitro, $C_{1\text{-}5}$ alkylthio, trifluoromethyl or trifluoromethoxy;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C_{1-5} alkyl, C_{3-8} cycloalkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{1-5} alkoxy, C_{1-5} alkylthio, C_{1-5} alkylsulfinyl, C_{1-5} alkylsulfonyl, cyano, nitro, hydroxy, $-CO_2R^{19}$, $-C(=O)R^{20}$, $-CONR^{21}R^{22}$, $-OC(=O)R^{23}$, $-NR^{24}CO_2R^{25}$, $-S(=O)_rNR^{26}R^{27}$, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and $-N(R^{28})R^{29}$;

 R^8 is hydrogen, $C_{1\text{--}10}$ alkyl, $C_{3\text{--}8}$ cycloalkyl, $C_{3\text{--}8}$ cycloalkyl- $C_{1\text{--}5}$ alkyl, aryl or aryl- $C_{1\text{--}5}$ alkyl;

 R^9 and R^{10} are the same or different, and independently are hydrogen, C_{1-5} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-5} alkyl, aryl or aryl- C_{1-5} alkyl; or R^9 and R^{10} form a ring selected from saturated 3 to 8 membered ring with the attached nitrogen atom, wherein one of the carbon atoms of such saturated 3 to 8 membered ring is optionally replaced by an oxygen or sulfur atom or by N-Z wherein Z is hydrogen, benzyl or C_{1-5} alkyl;

R¹¹ is hydrogen, halogen or C₁₋₅alkyl;

 R^{12} , R^{13} , R^{14} and R^{15} are the same or different, and independently are hydrogen or C_{1-5} alkyl;

R¹⁶, R¹⁹ and R²⁵ are the same or different, and independently are hydrogen or C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, aryl or aryl-C₁₋₅alkyl;

 R^{17} , R^{18} , R^{20} , R^{21} , R^{22} , R^{23} , R^{24} , R^{26} , R^{27} , R^{28} and R^{29} are the same or different, and independently are hydrogen, C_{1-5} alkyl or C_{3-8} cycloalkyl;

r is 1 or 2)

, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, pharmaceutically acceptable prodrugs thereof or pharmaceutically acceptable salts and hydrates thereof.

2. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 1 represented by the following formula [III]:

$$X-(CHR^3)_{\overline{h}}(CR^1R^2)_{m}$$

$$R^5$$

$$N$$

$$N$$

$$R^6$$

$$[IIII]$$

(wherein X, m, n, the cyclic amino group, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

- 3. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and –N(R²⁸)R²⁹ (wherein R²⁸ and R²⁹ are the same or different, and independently are hydrogen or C₁₋₃alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
- 4. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is cyano; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is 0 or 1; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C_{1-3} alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
- 5. The thienopyrimidine derivative substituted with the cyclic amino group

33

according to claim 2 represented by formula [III], wherein X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and –N(R²⁸)R²⁹ (wherein R²⁸ and R²⁹ are the same or different, and independently are hydrogen or C₁₋₃alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

- 6. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is hydroxy; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C_{1-3} alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
- 7. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is $-CO_2R^8$ or $-CONR^9R^{10}$; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; R^8 is hydrogen or C_{1-10} alkyl; R^9 and R^{10} are the same or different, and independently are hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{28})R^{29}$ (wherein R^{28} and R^{29} are the same or different, and independently are hydrogen or C_{1-3} alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

- 8. The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is $-CO_2R^8$ or $-CONR^9R^{10}$; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; R^8 is hydrogen or C_{1-10} alkyl; R^9 and R^{10} are the same or different, and independently are hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C_{1-3} alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
- 9. The thienopyridine derivative substituted with the cyclic amino group according to claim 1 represented by the following formula [IV]:

$$X-(CHR^3)_{\overline{h}}(CR^1R^2)_m$$
 S Ar $[IV]$ R^5 R^6

(wherein X, m, n, the cyclic amino group, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R¹¹ and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

10. The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; R¹¹ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and –N(R²⁸)R²⁹ (wherein R²⁸ and R²⁹ are the same or different, and independently are hydrogen or C₁₋₃alkyl), individual isomers

35

thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

- 11. The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is cyano; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is 0 or 1; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; R¹¹ is hydrogen; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C₁₋₃alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
- 12. The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; R¹¹ is hydrogen or C₁₋₅alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and –N(R²⁸)R²⁹ (wherein R²⁸ and R²⁹ are the same or different, and independently are hydrogen or C₁₋₃alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
- 13. The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is hydroxy; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R¹, R², R⁴ and R⁵ are hydrogen; R⁶ is C₁₋₅alkyl; R⁷ is hydrogen or C₁₋₅alkyl; R¹¹ is hydrogen; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C₁₋₃alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

- 14. The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is $-CO_2R^8$ or $-CONR^9R^{10}$; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; R^8 is hydrogen or C_{1-10} alkyl; R^9 and R^{10} are the same or different, and independently are hydrogen or C_{1-5} alkyl; R^{11} is hydrogen or C_{1-5} alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{28})R^{29}$ (wherein R^{28} and R^{29} are the same or different, and independently are hydrogen or C_{1-3} alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
- 15. The thienopyridine derivative substituted with the cyclic amino group according to claim 2 represented by formula [IV], wherein X is $-CO_2R^8$ or $-CONR^9R^{10}$; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3; R^1 , R^2 , R^4 and R^5 are hydrogen; R^6 is C_{1-5} alkyl; R^7 is hydrogen or C_{1-5} alkyl; R^8 is hydrogen or C_{1-10} alkyl; R^9 and R^{10} are the same or different, and independently are hydrogen or C_{1-5} alkyl; R^{11} is hydrogen; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C_{1-3} alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
- 16. Compounds represented by formula [I] according to claim 1, which compounds are selected from the group consisting of
- $\label{lem:condition} $$\{1-[7-(4-Bromo-2,6-dimethyl-phenyl)-2-methyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl\}-methanol,$
- {1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-methanol,

37

- 2-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-ethanol,
- {1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-acetonitrile,
- {1-[3-(2,4-dichloro-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-methanol,
- {1-[5-methyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-methanol,
- {1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-methanol,
- {1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-methanol,
- {1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-methanol,
- {1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-methanol,
- 2-{1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-ethanol,
- 2-{1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-ethanol,
- 2-{1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-ethanol,
- 2-{1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-ethanol,
- 1-[5-methyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidine-3-carbonitrile,
- {1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile,
- {1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile,
- {1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile
 - and {1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-

38

piperidin-4-yl}-acetonitrile.

17. An antagonist for CRF receptors, comprising a thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claims 1 to 16, as an active ingredient.

18. Use of a thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claim 1 to 16, for the manufacture of a therapeutic agent as an antagonist for CRF receptors.

INTERNATIONAL SEARCH REPORT

International Application No PCT/JP2005/000318

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D495/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) $IPC\ 7\ C07D$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, PAJ, WPI Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/02549 A (TAISHO PHARMACEUTICAL CO., LTD; NAKAZATO, ATSURO; KUMAGAI, TOSHIHITO;) 10 January 2002 (2002-01-10) cited in the application page 1, line 2 - line 10 page 4, line 9 - line 10 page 5, form (11) page 78, line 19 - page 79, line 2	1-18
A	WO 97/29110 A (JANSSEN PHARMACEUTICA N.V; NEUROCRINE BIOSCIENCES INC; CHEN, CHEN; WEB) 14 August 1997 (1997-08-14) cited in the application page 1, line 5 - line 8 page 3, Formula (I) Table 2, Co. No. 36-40 Table 3, Co. No. 59, 60 page 11, line 32 - page 12, line 2	1-18

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone. "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled.
"P" document published prior to the international filing date but later than the priority date claimed	in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
21 June 2005	28/06/2005
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx 31 651 epo nl, Fax (+31–70) 340–3016	Hoepfner, W

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP2005/000318

		PCT/JP2005/000318				
	C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.			
A	WO 98/47903 A (JANSSEN PHARMACEUTICA N.V; NEUROCRINE BIOSCIENCES INC; WEBB, THOMAS, R) 29 October 1998 (1998-10-29) cited in the application page 1, line 5 - line 8 page 3, Formula (I) page 11, line 36 - page 12, line 5		1–18			

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP2005/000318

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0202549 A	10-01-2002	AU BG CCN CCA EP WO PK WO PK US TUS Z	6943701 A 107374 A 0112166 A 2412287 A1 1439001 A 1535968 A 20024229 A3 5289 B1 200300007 A 1299378 A1 0301165 A2 0202549 A1 2004502685 T PA02012820 A 20026125 A 358411 A1 132003 A3 591022 B 2004034061 A1 2005009874 A1 200210041 A	14-01-2002 30-09-2004 02-09-2003 10-01-2002 27-08-2003 13-10-2004 18-06-2003 30-12-2004 16-08-2004 09-04-2003 28-08-2003 10-01-2002 29-01-2004 14-05-2003 04-02-2003 09-08-2004 05-08-2003 11-06-2004 13-01-2005 11-12-2003
WO 9729110 A	14-08-1997	AT AU CA DE DK WO EP SID NO NZ PT US US ZA	208395 T 725674 B2 1720997 A 2233307 A1 69708059 D1 69708059 T2 882051 T3 9729110 A1 0882051 A1 2167710 T3 15904 A 2000504678 T 981356 A 330118 A 882051 T 448178 B 6255310 B1 2002052362 A1 9700988 A	15-11-2001 19-10-2000 28-08-1997 14-08-1997 13-12-2001 18-07-2002 25-02-2002 14-08-1997 09-12-1998 16-05-2002 14-08-1997 18-04-2000 09-07-1998 27-03-2000 29-04-2002 01-08-2001 03-07-2001 02-05-2002 07-09-1998
WO 9847903 A	29-10-1998	AU AU CA WO EP JP NZ TW US ZA	751710 B2 7526898 A 2272292 A1 9847903 A1 0977759 A1 2002501493 T 335823 A 495511 B 6211195 B1 9803351 A	22-08-2002 13-11-1998 29-10-1998 29-10-1998 09-02-2000 15-01-2002 29-06-2001 21-07-2002 03-04-2001 21-10-1999